Aberrant methylation of the maspin promoter is an early event in human breast cancer

Bernard W Futscher, Megan M. O'Meara, Christina J. Kim, Margaret A. Rennels, Di Lu, Lynn M. Gruman, Richard E B Seftor, Mary J C Hendrix, Frederick E. Domann

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The maspin gene functions as a tumor suppressor in human breasts, and its expression is frequently lost during breast cancer progression. In vitro models of human breast cancer indicate that the loss of maspin expression is closely linked to aberrant methylation of the maspin promoter. We conducted a study on 30 archival ductal carcinoma in situ (DCIS) specimens to determine if aberrant methylation of the maspin promoter occurred in vivo, and whether it occurred early in breast cancer evolution. Healthy tissue obtained from reduction mammoplasty was used as normal control. Results from immunohistochemical analysis indicate that maspin expression is lost in a substantial fraction of DCIS specimens (57%). Bisulfite sequencing of DNA isolated from laser capture-microdissected normal and neoplastic ducts showed that loss of maspin expression was often, but not always, linked to aberrant methylation of the maspin promoter, suggesting that other mechanisms, in addition to aberrant methylation, participate and/or cooperate to silence maspin gene expression. Taken together, these results indicate that aberrant methylation of the maspin promoter is an early event in human breast cancer.

Original languageEnglish (US)
Pages (from-to)380-389
Number of pages10
JournalNeoplasia
Volume6
Issue number4
DOIs
StatePublished - Jul 2004

Fingerprint

Methylation
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
SERPIN-B5
Mammaplasty
DNA Sequence Analysis
Breast
Lasers
Gene Expression
Genes
Neoplasms

Keywords

  • Breast cancer
  • Laser capture microdissection
  • maspin
  • Methylation
  • Tumor suppressor

ASJC Scopus subject areas

  • Cancer Research

Cite this

Futscher, B. W., O'Meara, M. M., Kim, C. J., Rennels, M. A., Lu, D., Gruman, L. M., ... Domann, F. E. (2004). Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia, 6(4), 380-389. https://doi.org/10.1593/neo.04115

Aberrant methylation of the maspin promoter is an early event in human breast cancer. / Futscher, Bernard W; O'Meara, Megan M.; Kim, Christina J.; Rennels, Margaret A.; Lu, Di; Gruman, Lynn M.; Seftor, Richard E B; Hendrix, Mary J C; Domann, Frederick E.

In: Neoplasia, Vol. 6, No. 4, 07.2004, p. 380-389.

Research output: Contribution to journalArticle

Futscher, BW, O'Meara, MM, Kim, CJ, Rennels, MA, Lu, D, Gruman, LM, Seftor, REB, Hendrix, MJC & Domann, FE 2004, 'Aberrant methylation of the maspin promoter is an early event in human breast cancer', Neoplasia, vol. 6, no. 4, pp. 380-389. https://doi.org/10.1593/neo.04115
Futscher, Bernard W ; O'Meara, Megan M. ; Kim, Christina J. ; Rennels, Margaret A. ; Lu, Di ; Gruman, Lynn M. ; Seftor, Richard E B ; Hendrix, Mary J C ; Domann, Frederick E. / Aberrant methylation of the maspin promoter is an early event in human breast cancer. In: Neoplasia. 2004 ; Vol. 6, No. 4. pp. 380-389.
@article{75431a3c2ecc49bdb58facef8255f7be,
title = "Aberrant methylation of the maspin promoter is an early event in human breast cancer",
abstract = "The maspin gene functions as a tumor suppressor in human breasts, and its expression is frequently lost during breast cancer progression. In vitro models of human breast cancer indicate that the loss of maspin expression is closely linked to aberrant methylation of the maspin promoter. We conducted a study on 30 archival ductal carcinoma in situ (DCIS) specimens to determine if aberrant methylation of the maspin promoter occurred in vivo, and whether it occurred early in breast cancer evolution. Healthy tissue obtained from reduction mammoplasty was used as normal control. Results from immunohistochemical analysis indicate that maspin expression is lost in a substantial fraction of DCIS specimens (57{\%}). Bisulfite sequencing of DNA isolated from laser capture-microdissected normal and neoplastic ducts showed that loss of maspin expression was often, but not always, linked to aberrant methylation of the maspin promoter, suggesting that other mechanisms, in addition to aberrant methylation, participate and/or cooperate to silence maspin gene expression. Taken together, these results indicate that aberrant methylation of the maspin promoter is an early event in human breast cancer.",
keywords = "Breast cancer, Laser capture microdissection, maspin, Methylation, Tumor suppressor",
author = "Futscher, {Bernard W} and O'Meara, {Megan M.} and Kim, {Christina J.} and Rennels, {Margaret A.} and Di Lu and Gruman, {Lynn M.} and Seftor, {Richard E B} and Hendrix, {Mary J C} and Domann, {Frederick E.}",
year = "2004",
month = "7",
doi = "10.1593/neo.04115",
language = "English (US)",
volume = "6",
pages = "380--389",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Aberrant methylation of the maspin promoter is an early event in human breast cancer

AU - Futscher, Bernard W

AU - O'Meara, Megan M.

AU - Kim, Christina J.

AU - Rennels, Margaret A.

AU - Lu, Di

AU - Gruman, Lynn M.

AU - Seftor, Richard E B

AU - Hendrix, Mary J C

AU - Domann, Frederick E.

PY - 2004/7

Y1 - 2004/7

N2 - The maspin gene functions as a tumor suppressor in human breasts, and its expression is frequently lost during breast cancer progression. In vitro models of human breast cancer indicate that the loss of maspin expression is closely linked to aberrant methylation of the maspin promoter. We conducted a study on 30 archival ductal carcinoma in situ (DCIS) specimens to determine if aberrant methylation of the maspin promoter occurred in vivo, and whether it occurred early in breast cancer evolution. Healthy tissue obtained from reduction mammoplasty was used as normal control. Results from immunohistochemical analysis indicate that maspin expression is lost in a substantial fraction of DCIS specimens (57%). Bisulfite sequencing of DNA isolated from laser capture-microdissected normal and neoplastic ducts showed that loss of maspin expression was often, but not always, linked to aberrant methylation of the maspin promoter, suggesting that other mechanisms, in addition to aberrant methylation, participate and/or cooperate to silence maspin gene expression. Taken together, these results indicate that aberrant methylation of the maspin promoter is an early event in human breast cancer.

AB - The maspin gene functions as a tumor suppressor in human breasts, and its expression is frequently lost during breast cancer progression. In vitro models of human breast cancer indicate that the loss of maspin expression is closely linked to aberrant methylation of the maspin promoter. We conducted a study on 30 archival ductal carcinoma in situ (DCIS) specimens to determine if aberrant methylation of the maspin promoter occurred in vivo, and whether it occurred early in breast cancer evolution. Healthy tissue obtained from reduction mammoplasty was used as normal control. Results from immunohistochemical analysis indicate that maspin expression is lost in a substantial fraction of DCIS specimens (57%). Bisulfite sequencing of DNA isolated from laser capture-microdissected normal and neoplastic ducts showed that loss of maspin expression was often, but not always, linked to aberrant methylation of the maspin promoter, suggesting that other mechanisms, in addition to aberrant methylation, participate and/or cooperate to silence maspin gene expression. Taken together, these results indicate that aberrant methylation of the maspin promoter is an early event in human breast cancer.

KW - Breast cancer

KW - Laser capture microdissection

KW - maspin

KW - Methylation

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=3142671918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142671918&partnerID=8YFLogxK

U2 - 10.1593/neo.04115

DO - 10.1593/neo.04115

M3 - Article

C2 - 15256060

AN - SCOPUS:3142671918

VL - 6

SP - 380

EP - 389

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 4

ER -